Repeat Injections of Ferumoxytol Well Tolerated
Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.
Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.
Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.
Mitochondrial DNA copy number (mtDNA) and plasma levels of hepcidin hold promise as novel markers of anemia in CKD patients, suggest data introduced at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Hemoglobin (Hb) levels in non-dialysis CKD patients treated with erythropoiesis-stimulating agents (ESAs) have been on the decline.
Administration of ergocalciferol (vitamin D2) to anemic hemodialysis (HD) patients receiving erythropoietin (EPO) may decrease EPO requirements, suggest data presented at the National Kidney Foundation 2010 Spring Clinical Meetings.
Anemic pre-dialysis CKD patients who were switched from darbepoetin to epoetin alfa (EPO) maintained similar hemoglobin levels but at a lower cost, according to a study presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Variant hemoglobin phenotypes, including sickle cell trait and hemoglobin C trait, may be associated with resistance to treatment with erythropoietin-stimulating agents (ESAs) among African Americans with end-stage renal disease (ESRD).
Hemodialysis (HD) patients hospitalized for infections receive significantly higher amounts of replacement IV iron therapy and cumulative iron dose, according to findings presented here at the National Kidney Foundation 2010 Spring Clinical Meetings.
ORLANDO, Fla.—Correcting iron deficiency in non-dialysis CKD patients lowers platelet counts and improves erythropoiesis, researchers reported here at the National Kidney Foundation’s 2010 Spring Clinical Meetings.